The Southwest Oncology Group is a major multi-disease, multi-disciplinary, multi-institution group engaged in cooperative cancer research. This organization now consists of 35 Member Institutions, 29 Community Clinical Oncology Programs (CCOPs), 230 Affiliates, and 26 Urologic Cancer Outreach Programs (UCOPs), who together accrue 5,000 patients to clinical trials each year. Currently there are 96 studies open for accrual in 14 committees. The Statistical Center is essential to the design, conduct, and analysis of the cancer research in the Southwest Oncology Group. Its main functions are: (1) to participate in the review of proposed protocols, particularly as regards experimental design, sample size, and feasibility; (2) to provide for registration of all patients on all studies, and for randomization where appropriate; (3) to develop Web and software technology for paperless submission of data; (4) to provide for review and quality control of data collected during studies; (5) to provide for data entry and for computer processing and storage and retrieval of data; (6) to work with the Group chair and other investigators in the Group to improve the quality of clinical trials through improved forms, more uniform and reproducible data definitions, and more economical flow of data; (7) to assist the Group chair in the administration of the Group; (8) to analyze and publish the results of studies in conjunction with the study coordinators; (9) to use the data collected to try to find new leads regarding prognostic factors and late effects; (10) to perform statistical research on the efficient design, conduct, and analysis of cancer clinical trials and cancer control research; and (11) to educate investigators, nurse oncologists and CRAs in statistical analysis, research design and the utilization of the most advanced scientific and data management strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA038926-19
Application #
6724999
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1985-01-01
Project End
2009-12-31
Budget Start
2004-07-23
Budget End
2004-12-31
Support Year
19
Fiscal Year
2004
Total Cost
$3,875,541
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Dai, James Y; Liang, C Jason; LeBlanc, Michael et al. (2018) Case-only approach to identifying markers predicting treatment effects on the relative risk scale. Biometrics 74:753-763
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sala Torra, Olga; Othus, Megan; Williamson, David W et al. (2017) Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. Biol Blood Marrow Transplant 23:691-696
Unger, Joseph M; Griffin, Katherine; Donaldson, Gary W et al. (2017) Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes 2:27
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2
Othus, M; Mukherjee, S; Sekeres, M A et al. (2016) Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia 30:1779-80
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7

Showing the most recent 10 out of 512 publications